ONCAlert | 2017 San Antonio Breast Cancer Symposium

Cobimetinib Plus Paclitaxel in TNBC

Adam M. Brufsky, MD, PhD
Published Online:11:55 AM, Wed February 1, 2017

Adam M. Brufsky, MD, PhD, professor of Medicine, associate chief of Hematology/Oncology, co-director of the Comprehensive Breast Care Center, associate director of Clinical Investigation, University of Pittsburgh, discusses combining cobimetinib (Cotellic) and paclitaxel as a first-line treatment in patients with advanced triple-negative breast cancer (TNBC).
Copyright © TargetedOnc 2017 Intellisphere, LLC. All Rights Reserved.